Colorectal cancer (CRC) is the third most prevalent cancer globally and the second deadliest cancer for both men and women. To change this situation, novel therapeutic approaches have been developed, with immunotherapy being one of the most promising. This technique employs the patient's immune system to identify and eradicate cancer cells. The intestinal microbiota is composed of various microorganisms, such as bacteria, viruses, protozoa, and fungi. This microbiome has vital functions for the human being, such as participation in digestion, vitamin production, protection against aggressive pathogens, and modulation of the immune system. Dysregulation of this homeostasis can generate injuries to the affected person, one of which is carcinogenesis. From this, the intestinal microbiota assumed a relevant role in this therapeutic process by acting in immunotherapy through its participation in blocking some immune checkpoints and, consequently, resulting in a greater efficiency in the cytotoxic activity of T cells. Therefore, this review aims to comprehend the mechanism by which the microbiota directly impacts the development of CRC and, especially, the mechanisms by which the microbiome generates better prognosis in cancer patients.